ArticleFrontiers in medicine2022
Effective Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus in an
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Pharmacovigilance and clinical insights into perindopril-induced thrombocytopenia: a case report of diagnostic challenges and therapeutic alternatives.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome.Frontiers in immunology · 2026Review
- Recent research advances in the development of Dabie Banda virus vaccines.PLoS neglected tropical diseases · 2024Review
- Calcium Influx Regulates the Replication of Several Negative-Strand RNA Viruses Including Severe Fever with Thrombocytopenia Syndrome Virus.Journal of virology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by the SFTS virus (SFTSV). This syndrome is endemic in China, South Korea, and Japan, with a fatality rate of approximately 20-30%. Although the World Health Organization has listed SFTS as a disease that requires urgent steps for the development of its treatment, no treatments are available. Methods: We analyzed the antiviral activity of 41 drugs against the SFTSV to explore potential therapeutic candidates using real-time reverse transcription-polymerase chain reaction and plaque assay Results: Peramivir, nitazoxanide, and favipiravir were found to have inhibitory effects on the SFTSV at concentrations below the maximum plasma concentration (Cmax). The concentrations that inhibited the SFTSV by 50% were as follows: peramivir, half maximal effective concentration (EC Conclusion: The effects of peramivir and nitazoxanide on the SFTSV were identified for the first time in this study. Future studies need to include animal models of SFTSV infection, clinical trials including dose-ranging trials, and evaluation of combination therapy with other potential antivirals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.